Health
Johnson & Johnson’s Coronavirus Vaccine Candidate Efficacious in Pre-Clinical Studies; Human Testing Has Begun – The Motley Fool
The company aims to start a phase 3 clinical trial for Ad26.COV2-S in September.
Johnson & Johnson(NYSE:JNJ) has gained some ground in the coronavirus vaccine race. On Thursday, the pharmaceutical and consumer goods company announced that in pre-clinical studies, its Ad26.COV2-S vaccine candidate had demonstrated effectiveness in protecting on non-human primates from infection with SARS-CoV-2.
In contrast to other coronavirus vaccine candidates — such as the one many observers view as the most promising, Moderna’s mRNA-1273 — Johnson & Johnson’s produced its respo…
-
Noosa News22 hours agoInside the final hours before Australian lawyer Christopher Saines died in Thai massage parlour
-
General20 hours agoGerman backpacker Carolina Wilga found alive in WA’s outback
-
Noosa News22 hours agoAustralian NFL player Laki Tasi comes home to convince kids to switch codes
-
Business22 hours agoHow $1,000 a month in this ASX ETF could turn into $500,000